GlassScriptPhysician profile
Rebecca L Walker
NPI 1336797018
$1,803.50
in general payments reported to CMS, 2019-2025
27 companies · $651 in 2025
The $651 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $124 · 2023: $433 · 2024: $595 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,640 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,640.49 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $388.79 | 2022-2025 | |
| Pfizer INC. | $264.11 | 2022-2025 | |
| Novo Nordisk INC | $260.65 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $150.76 | 2023-2025 | Veozah |
| Amgen INC. | $86.45 | 2022-2025 | Evenity, Prolia, Tavneos |
| Otsuka America Pharmaceutical, INC. | $83.14 | 2022-2025 | Rexulti |
| Grifols USA, LLC | $69.34 | 2023-2024 | Prolastin-C Liquid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.66 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $43.29 | 2023-2025 | Eliquis, Camzyos |
| Actelion Pharmaceuticals US, INC. | $41.62 | 2024 | Opsumit, Uptravi |
| Lundbeck LLC | $38.54 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.50 | 2022-2023 | Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $34.41 | 2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Glaxosmithkline, LLC. | $32.11 | 2025 | Bexsero, Shingrix |
| Phathom Pharmaceuticals, INC. | $29.82 | 2024-2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $22.89 | 2025 | Andembry |
| Sanofi-Aventis U.S. LLC | $20.50 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.74 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $18.74 | 2025 | Austedo Xr |
| Ultragenyx Pharmaceutical INC. | $16.42 | 2023 | |
| Medtronic, INC. | $16.38 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $16.30 | 2023 | Prehevbrio |
| Biogen, INC. | $15.72 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.37 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.25 | 2024 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $12.81 | 2023 | Livalo, Seglentis |
| Currax Pharmaceuticals LLC | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.